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Since the identiﬁcation of APOBEC3G (A3G) as a potent restriction factor of HIV-1, a tremendous amount of eﬀort has led
to a broadened understanding of both A3G and the APOBEC3 (A3) family to which it belongs. In spite of the ﬁne-tuned viral
counterattack to A3 activity, in the form of the HIV-1 Vif protein, enthusiasm for leveraging the Vif:A3G axis as a point of
clinical intervention remains high. In an impressive explosion of information over the last decade, additional A3 family members
have been identiﬁed as antiviral proteins, mechanistic details of the restrictive capacity of these proteins have been elucidated,
structure-function studies have revealed important molecular details of the Vif:A3G interaction, and clinical cohorts have been
scrutinized for correlations between A3 expression and function and viral pathogenesis. In the last year, novel and unexpected
ﬁndingsregardingtheroleofA3Ginimmunityhaverefocusedeﬀortsonexploringthepotentialofharnessingthenaturalpowerof
this immune defense. These most recent reports allude to functions of the A3 proteins that extend beyond their well-characterized
designation as restriction factors. The emerging story implicates the A3 family as not only defense proteins, but also as participants
in the broader innate immune response.
1.Introduction
In 2002, the cloning of APOBEC3G (A3G; then called
CEM15) and the identiﬁcation of the protein product of this
gene as the ﬁrst cellular protein capable of restricting HIV-
1 infection revealed a novel direction for chemotherapeutic
intervention and ignited the search for additional defense
proteins capable of counteracting viral invasion [1]. The
report of this cloning solved a long-standing enigma in
the ﬁeld of HIV-1 pathogenesis. Early work examining and
comparing the pathogenesis of wild-type and Vif-deﬁcient
HIV-1 had yielded conﬂicting results with some laboratories
concluding that Vif was dispensable for productive infection
while other groups maintained that Vif expression was
essential [2–4]. Ultimately, it was decisively shown that the
requirement for Vif was cell-type dependent; permissive cells
supported the growth of HIV-1Δvif while nonpermissive
cellslimitedsuchviralreplication[5,6].Mostinterestingand
relevantwastheinabilityofVif-deﬁcientHIVtoproductively
infect primary CD4+ T cells, one of the critical natural
targets of HIV-1 infection [2, 3, 5, 7, 8]. The molecular
explanation for the “Vif phenotype” remained unexplained
for the subsequent decade. Proﬀered in this early work was
the idea that permissive cells expressed a cellular factor
that compensated for Vif. An equally valid suggestion was
that nonpermissive cells harbored an inhibitory activity of
HIV-1 that was itself overcome by the Vif protein. It was
subsequently established, in a pair of elegant experiments
utilizing heterokaryons formed from fusion of nonpermis-
sive and permissive cell lines that, in fact, nonpermissive cells
expressed an activity that suppressed HIV-1Δvif replication
[9, 10]. The genetic relatedness of two T lymphocyte lines,
one nonpermissive and the other permissive, was exploited
in a classical subtractive hybridization experiment; A3G was
identiﬁed as this described suppressive activity. It was found
tobealmostexclusivelyexpressed bynonpermissive cellsand
itsstableexpressioninpermissivecellsconveyedtheabilityto
resist an HIV-1 challenge [1].2 Molecular Biology International
It was quickly appreciated that A3G was but one family
member of a previously identiﬁed gene locus [11]. Sub-
sequent investigation also revealed that A3G exhibited a
potent DNA-mutating ability [12]. In humans, seven family
members within the locus have been identiﬁed; rhesus
macaques, the nonhuman primate that serves as the most
important animal model for HIV treatment and vaccine
testing, also have seven APOBEC3 genes, while the murine
genome contains a single A3 gene [13–15]. In each of these
organisms, the role the A3 genes play in counteracting viral
invasion is critical. All seven A3 family members identiﬁed
in humans exhibit powerful suppressive activity against a
range of viruses while the homologous proteins in mice
and primates appear to perform similar functions [16–18].
WhileA3inhibitoryactivityisrelativelybroad,themostwell-
characterized and studied function is their striking ability to
restrict retroviral infection [19]. In an evolutionary response
to this restriction, the retroviruses have countered with a
battery of genes exquisitely ﬁne-tuned to overcome these
endogenous defense proteins.
2. The Laboratory Setting
Withoneexception(A3C),eachofthesevenA3familymem-
bersinhumanshasbeenobservedtobecapableofcombating
HIV-1 [1, 17, 20–27]. Whether the antiviral activity observed
is relevant during the course of a natural HIV-1 infection
has not been unequivocally established for any of the family
members and there are valid concerns raised in the interpre-
tation of various data regarding levels of protein expression
and potency. However, it is becoming increasingly clear that
understanding the battle that is waged between the innate
immune system and HIV-1 during acute infection is imper-
ative and the A3 proteins are critical players in this initial
encounter.
While the relative potencies of individual A3 family
members in the setting of a natural infection have been diﬃ-
cult to assess, it has been convincingly established that, in the
tissue culture setting, A3G exhibits the most potent activity
against HIV-1. In a variety of cell types, both primary cells
and established cells lines, and under varying experimental
conditions, including both single-round infectivity assays
and multiple-round replication assays, A3G suppresses the
infectivity of HIV-1. HIV-1 Vif has evolved to counteract this
impressive activity of A3G by preventing virion encapsida-
tion of this host factor [28–35] .V i fa c t sa sa na d a p t e rp r o t e i n
bridging A3G and a Cullin5-elongin B/C-Rbx ubiquitin
ligase [36]. Within this complex A3G is ubiquitinylated and
subsequentlydegradedinthe26Sproteasome[36,37].Other
modalities involving Vif prevention of A3G encapsidation
have also been documented [28, 32, 34]. Interestingly,
dominance of A3G over Vif has been noted under conditions
of elevated and/or stabilized expression [1, 34, 36]. This
ability to suppress HIV-1 even in the presence of Vif is note-
worthy as it has distinct implications for the development of
chemotherapeutics designed to interfere with the A3G:Vif
axis.
The anti-HIV-1 functionality of A3G is multifaceted.
Its most extensively characterized anti-HIV-1 function is its
ability to catalyze cytidine deamination of HIV-1 DNA on
the minus strand resulting in the detection of guanosine-
to-adenosine transition mutations in reverse transcripts;
upwards of 10% of guanosines may be mutated leading to
the labeling of this A3G-mediated process as hypermutation
[34, 38, 39]. The fate of such hypermutated transcripts is
not well understood, but certainly this dramatic mutational
burden eﬀectively short-circuits viral infection.
Work from multiple groups has also uncovered deami-
nation-independent anti-HIV eﬀects of A3G that are seen
during viral infection [22, 40–49]. The characterization of
this editing-independent antiviral function has suggested a
block to viral replication that occurs after entry but before
integration. While the molecular details of this deaminase-
independent function of A3G remain unclear, defective
reverse transcription products are commonly observed,
indicating that A3G likely acts during the process of reverse
transcription. A more comprehensive understanding of this
inhibition will be important. All members of the A3 family
contain at least one conserved cytidine deaminase active site
(CDA;familymembersA3B,A3D,A3F,andA3Gcontaintwo
such domains) composed of the signature sequence His/Cys-
X-Glu-X23–28-Pro-Cys-X2-Cys [11, 15]. Early structure-
function analysis of A3G was performed by disrupting these
suspected catalytic domains with site-directed mutagenesis
[41]. The conserved histidine, glutamic acid, and cysteine
resides in both the N-terminal and C-terminal domains of
A3G were individually mutated and the resulting proteins
were independently examined for their catalytic function
as well as their ability to suppress HIV-1Δvif infection.
The data clearly indicated that the C-terminal CDA domain
was responsible for A3G enzymatic function. Unexpectedly
the data also suggested that, under speciﬁc experimen-
tal conditions, signiﬁcant anti-HIV-1 inhibition could be
imparted in the absence of the characteristic mutagenic
activity. Subsequent work in a range of experimental systems
has supported these original observations. Controversy over
these observations primarily stems from claims that these
data have most often been cited in experimental settings
using mutant A3G exhibiting elevated expression levels [41,
42, 50, 51]. In attempts to clarify the role of A3G expression
levels a number of groups have compared A3G protein
expression in transiently transfected cell lines and primary
CD4+ T cells/macrophages, reporting that expression levels
achieved during transient transfectionexceedlevels observed
in primary cells. However, a few cautionary notes are
warranted. A3G that is mutated, for instance, at the critical
glutamic acid at residue 259 of the protein, has also been
shown to have a more limited ability to block the process of
reverse transcription thereby suggesting that distinguishing
deamination-dependent and -independent activities may
be challenging [16]. Additional support for a pleiotropic
antiviral function of A3G is provided by observations in
which the A3G phenotype is unaﬀected in cells that do
not express uracil DNA glycosylase 2 or SMUG, enzymes
responsiblefortheremovalofuracilsfromsingle-ordouble-
stranded DNA [52, 53]. As a signiﬁcant suppressor of HIV-1,Molecular Biology International 3
a multipronged ability of A3G to inhibit HIV-1 would have
notable beneﬁts to the invaded host.
Using a variety of cell lines and experimental condi-
tions, the anti-HIV-1 activity of A3B, A3D, A3F, and A3H
(haplotypes I, II, V, and VII) has also been conclusively
demonstrated [17, 20, 21, 23–25, 27, 54, 55]. Hypermuta-
tion is often recorded as coincident with antiviral activity,
although, in the case of A3B and A3F, as with A3G, there
are observations of HIV-1 suppression in the absence of
hypermutation [24, 42, 43]. Sensitivity to Vif regulation
has been observed for A3D, A3F, A3G and A3H while A3B
and A3H/Haplotype I resist Vif-mediated virion exclusion
and thus exhibit detectable activity against wild-type HIV-
1 virus. However, not all of these family members are
equally likely to contribute to HIV-1 resistance during a
natural infection; A3B is primarily expressed in B cells and
makes it unlikely that this protein contributes appreciably to
inhibition of HIV-1 [17, 20, 21, 23, 24, 56–58]. Similarly, the
expression of the A3H/Haplotype I restricts wildtype HIV-
1, but the protein is inherently unstable [20, 56]. A question
with important clinical implications is whether this intrinsic
instability may be overcome while harnessing the natural
power to combat wild-type viral infection [58, 59].
Until recently, the role of A3A in HIV-1 inhibition was
unappreciated outside of two signiﬁcant observations: the
ﬁrst being a correlation between its expression in monocytes
and the susceptibility of these cells to HIV-1 infection, and
the second was that expression of A3A was conﬁned to cells
of the myeloid lineage and this expression was positively
regulated by INF-α [60–62]. Berger et al. have now described
a novel and critical role A3A plays in the early phase
of HIV infection, speciﬁcally in myeloid cells [22]. When
primary myeloid cells were infected with HIV-1 and the
induction of expression at the A3 locus was examined, it
was shown that these cells preferentially induced A3A,o n
both the mRNA and protein levels; induction of other A3
family members in these cells was not detected and A3A
induction in peripheral blood lymphocytes was negligible.
The induced A3A was protective upon HIV-1 challenge and
depletionofA3Ainprimarymacrophagesanddendriticcells
increased viral replication in both single-round infectivity
assays and a spreading infection. Similar to other A3 proteins
this viral restriction was primarily observed as a profound
suppression in the accumulation of viral DNA suggesting
interference with an early step of reverse transcription;
limited editing of viral reverse transcripts was detectable,
but the evidence suggested that enzymatic function was not
thesoleantiviralfunction.Notwithstanding itscommonrole
as an A3 family member involved in HIV-1 control, A3A
exerts its antiviral function uniquely. It is not producer cell-
derived A3A that impacts virus replication, but rather it is
the pool of A3A present in the actual target cell itself that
inhibits incoming HIV-1 particles. Data from independent
laboratories strongly support these conclusions for this role
of A3A in target myeloid cells [63–65].
Within cells of the myeloid lineage, A3A appears to be
the critical suppressor, exerting its eﬀect independently of its
editing ability. In CD4+ T cells in the tissue culture model
of infection, A3G activity dominates, and its inhibitory
function is exerted utilizing both editing-dependent and
-independent mechanisms. A3A functions in the target
cell while A3G functions in the producer cell. Recent
observations, however, have now suggested an unexpected
and intricate antiviral role played by the A3G expressed in
target cells [66]. Expression of either A3A or A3G activate
the cellular DNA damage response (DDR) [67]. In the
case of A3A, a G1/S-phase cell cycle arrest is also induced
and its catalytic domain is implicated in the eﬀect. While
the relevance of these interesting observations in regard
to HIV-1 infection is not immediately obvious (the A3A
experiments were performed in human osteosarcoma cells)
the role that the DDR response pathway plays in the innate
immune response has only recently been explored and
appreciated [68, 69]. Experimental observations support the
idea that triggering the DDR pathway acts as an alerting
mechanism for the innate immune system [66, 68, 70,
71]. In the emerging A3G story this certainly seems to
be the case (Figure 1). Norman et al. examined expression
of the critical Natural killer (NK) cell-activating ligand,
NKG2D-L, in HIV-1-infected primary CD4+ T cells [66].
They compared expression of NKG2D-L under conditions
of wildtype HIV-1 infection and HIV-1Δvif infection and
found a surprising discrepancy: the combination of Vpr
and A3G in the HIV-1Δvif infections activated the DDR
ultimately leading to the upregulation of both A3G and
NKG2D-L. Increased expression of NKG2D-L sensitized the
HIV-1-infected cell to NK-mediated killing. In the presence
of Vif this NK-mediated killing was blunted. The role of
target cell-expressed A3G was further veriﬁed using shRNA’s
targeting A3G mRNA; loss of A3G in an HIV-1Δvif setting
resulted in diminished NK-killing and increased (infected)
cell survival. The authors suggest that, in a natural infection,
the A3G-dependent sensitization of HIV-1-infected cells to
NK-mediated killing is hindered by the loss of A3G through
Vif-mediateddegradation.Itbearsmentioningthatinfection
of murine primary B cells with the transforming retrovirus
Abelson murine leukemia virus (Ab-MuLV) also leads to the
inductionofactivation-induceddeaminase(AID)expression
[72]. AID is a member of the larger APOBEC-AID family
of cytidine deaminases (this grouping includes the founding
member, APOBEC1, APOBEC2, APOBEC3A-H and AID).
This induction of AID also results in the upregulation of
an NKG2D ligand, rendering the infected cells susceptible
to NK-mediated lysis. The in vivo eﬀect is the profound
containment of Ab-MuLV replication and the ability of
the host animals to restrict the virus and survive this
pathogenic encounter. This indirect eﬀect of AID is also
linked to the DDR-stimulated signaling pathways. Details
on the mechanistic details of these antiviral functions have
not yet been fully characterized. Particularly intriguing
is whether the catalytic function of A3G and/or AID is
necessary for these eﬀects, and, if so, how is this enzymatic
capacity utilized. With the description of the involvement
of the DDR, it is suspected that the signature cytidine
deaminasemodalitywouldbeimportantbutconﬁrmationof
such speculation is warranted. Based on these observations,
therapeutic approaches that interfere with the process of Vif-
regulated degradation of A3G could potentially strengthen4 Molecular Biology International
CCUA
GGAT
A3G
A3G
A3G
A3G
A3G
UNG
CC  A
GGAT
Vpr
DDR
A3G
A3G
NK cell
Producer cell
NKG2D 
receptor
CCUA
GGAT
Cytidine deaminase-
mediated hypermutation, 
impaired reverse 
transcription A3G
A3G
A3G
A3G
A3G
A3G
Target cell
A3G
A3G
A3G
A3G
Pool of target
cell-expressed
A3G NKG2D-L
NKG2D-L
HIV-1Δvif infection
Figure 1: A3G can exert multiple antiviral eﬀects against HIV-1 infection. Virion-packaged A3G restricts HIV-1Δvif replication via cytidine
deaminase-mediated hypermutation as well as interfering with eﬃcient reverse transcription. Additionally, the introduction of the uridines
into the minus-strand DNA during reverse transcription triggers the DNA damage response (DDR). This induction of DDR involves
other proteins, including the host protein, UNG, and the HIV-1 Vpr protein. Among other downstream eﬀects, the DDR stimulates the
transcriptional synthesis of NKG2D ligands. The subsequent expression of these proteins on the surface of the HIV-infected cell sensitizes it
to NK cell lysis. It should also be noted that A3G expression within the target cell (designated as dotted symbols to distinguish it from the
virion-packaged A3G). Also critically participates in the DDR activation.
not only a potent intracellular defense, but also impact the
ability of NK cells to attack infected cells.
3.The Pictureinthe Clinic
As astounding as our progress has been in understand-
ing the molecular and mechanistic details of A3 proteins
and their interaction with HIV-1, providing data for the
in vivo relevance of A3 activity has been signiﬁcantly
more challenging. Experiments manipulating A3G in the
laboratory have supported the proposition that elevated
expression levels of this restriction factor can and do alter
wildtype HIV-1 infectivity; clinical correlates of this in
vitro o b s e r v a t i o nh a v eb e e nm o r ed i ﬃcult to gather. With
few exceptions, the clinical work to date has principally
focused on A3G and the eﬀect its ﬂuctuating expression
levels and catalytic activity can have on HIV-1 infection and
progression. Clinical analyses do not often lend themselves
to large sample sets, and the confounding combinatorial
eﬀects of host genetics and environment strain eﬀorts of
reproducibility. With these openly acknowledged limitations
recognized,thereremainsanincreasingamountofsuggestive
evidence that corroborates the idea that A3G expression
and/oractivitycanmodulatenaturalHIV-1infection[59,75,
77, 79–81]( Table 1).
In infected individuals, hypermutated HIV-1 proviral
genomes and elevated A3G expression levels have been
correlated with both lower viral loads and increased CD4+
T cells counts [75, 80–83]. In a relatively large study, Land et
al. noted the signiﬁcant association between proviral hyper-
mutation and increased peripheral blood CD4+ T cell count.
A3G expression was not directly quantiﬁed and the detected
hypermutation was used as a surrogate for catalytic function
of A3G.
More direct analysis of A3G expression in the setting of
a natural HIV-1 infection has also yielded tantalizing hints
of A3G control. Working with a small cohort of women, one
group recently reported an interesting correlation betweenMolecular Biology International 5
Table 1: Clinical studies correlating A3 family members and HIV-1 pathogenesis.
A3 Family member Correlation reported Identiﬁcation of cohort Reference
A3B
Homozygous deletion of gene associated
with higher: rates of HIV infection after
exposure, viral set point, and rate of disease
progression
4216 HIV+ patients pooled from 5
longitudinal cohorts: ALIVE, MACS, SFCC,
HGDS and MHCS [73] (US-based studies)
An et al. [74]
A3F and A3G
Level of detectable proviral hypermutations
that exhibited A3F/A3G cytidine deaminase
signatures associated with higher CD4+ cell
count
215 HIV+ female commercial sex workers
plus 25 HIV+ women who were infected
perinatally (Nairobi, Kenya)
Land et al. [75]
A3F and A3G
Elevated expression of A3F and A3G in
PBMCs associated with establishment of
lower viral set point
30 women from a well-established [76]
cohort of female commercial sex workers
(Dakar, Senegal)
Ulenga et al. [77]
A3G 186R polymorphism in African Americans
associated with rapid progression to AIDS
2430 HIV+ patients pooled from 5
longitudinal cohorts: ALIVE, MACS, SFCC,
HGDS and MHCS [73] (US-based studies)
An et al. [78]
A3G
Elevated expression of A3G in CD14+ cells
associated with resistance to HIV-1 infection
after exposure
30 HESN individuals (Florence, Italy) Biasin et al. [79]
A3G Elevated expression levels inversely
associated with viral load in LTNPs
6 uninfected volunteers; 17 HIV+
progressors; 8 HIV+ LTNPs Jin et al. [80]
A3G
C40693T polymorphism, located within
intronic sequences, associated with
increased risk of infection
122 HIV-exposed individuals; 69 sero
converted after exposure, 53 retained
seronegative status (Montreal, Canada)
Valcke et al. [73]
A3G
HESN individuals expressed elevated levels
of A3G when compared to healthy controls;
elevated levels of A3G associated with higher
CD4+ cell count in HIV+ patients
26 healthy controls, 37 HESN individuals,
45 HIV+ patients (Mexico City, Mexico)
V´ azquez-P´ erez et al.
[81]
A3H Haplotype I associated with protection from
HIV-1 infection 70 serodiscordant couples (Florence, Italy) Cagliani et al. [59]
HESN: highly exposed seronegative; LTNP: long-term nonprogressors.
individuals expressing higher levels of A3G before HIV-
1 infection with the establishment of a lower viral set
point after infection [77]. Perhaps the most interesting
cohorts in which to examine A3G expression levels and
the importance of these levels during viral infection in
vivoarelong-termnonprogressors(LTNPs),elitesuppressors
(ESs), and highly exposed seronegative (HESN) individuals.
To date, there has been no reporting of A3G expression
(or activity) as an explanation for the innate ability of
an ES to completely control the HIV-1 virus. However,
there has been an observation that elevated A3G levels do
correlate with higher CD4+ T cell counts and lower viremia
within a group of identiﬁed LTNPs, suggesting that, under
certain conditions, overexpression of A3G may be protective
[80]. Two independent studies, examining approximately
67 individuals who have been repeatedly exposed to HIV-
1, yet retain their seronegative status, have also presented
evidence that elevated A3G expression levels correlate with
viralrestriction[79,81].Amongstthesetwocohortsavariety
of cell types were studied, including PBMCs, CD4+ T cells,
CD8+ T cells, CD14+ monocytes, and cervical cells. These
cells were assayed for the level of A3G expression primarily
determined at the transcriptional level; in a small number
of instances, protein expression was also determined. Cal-
culated levels of mRNA and protein in HESN individuals
were then compared to both HIV+ individuals and healthy
controls and, in both experimental groups, HESN expressed
statistically higher levels of A3G expression. One study
carried the results further and was also able to show that
PBMCs isolated from HESN individuals were able to more
eﬀectively limit a wildtype HIV-1 challenge [79]. Interest-
ingly, both PBMCs and CD14+ cells, isolated from these
HESN individuals, appeared to exhibit higher responsiveness
to IFN-α treatment as measured by the induction of A3G
expression.
Finally, a recent experiment utilizing the SIV/macaque
model for HIV-1 infection also suggests that investigating
and understanding the consequences of increased A3G
(and A3F, in this case) expression levels may elucidate the
protective role these defense proteins can play in vivo [84].
Infected macaques were separated by clinical stage (chronic
versus AIDS stage of infection) and compared to uninfected
controls. In isolated PBMCs, CD4+ T cells, and peripheral
lymph nodes there was a demonstrated negative correlation
between A3F/G mRNA expression and viral loads. In addi-
tion, the diﬀerence in A3F/G expression between control
and infected animals was even more pronounced when
individuals whose disease course mimicked that of HIV-
1/LTNPswerespeciﬁcallycompared.Oneofthenovelaspects
of this reporting was the kinetic observation of the in vivo6 Molecular Biology International
regulation of A3G gene expression after SIV challenge. Seven
days after infection A3G expression levels began to rise and
this expression induction peaked on Day 10 after infection.
Peak viremia was measured on Day 14. The concomitant
rise of A3G levels, leading the rise of replicating virus
levels, suggests that the struggle for control between this
intracellular restriction factor and the invading pathogen
occurs early, during acute infection. This supports previous
reports noting the HIV-1-induction of A3G expression and
the critical importance this early encounter may play on
establishing viral set point [22, 79, 81, 84–86].
In spite of the meticulous analyses and important work
accomplished, the current clinical understanding of how
and whether A3 family members modulate HIV-1 infection
is limited and somewhat unsatisfactory. A consensus has
not yet emerged and such agreement will likely require a
more collaborative and coordinated eﬀort, across cohorts
and experimental approaches. The details of designing such
experiments are themselves still fraught with unknown
parameters; for instance, which cell types and/or tissues
should be examined? Is an examination of proviral hyper-
mutation or viral genome editing enough to serve as a
marker for A3G antiviral function? Is a measurement of A3G
mRNA suﬃcient to draw conclusions regarding expression
of the protein and resultant antiviral activity? At least two
groups have noted a disconcerting disconnect between A3G
mRNA and protein expression in PBMCs [60, 79]. Do other
A3 family members play distinct roles at discrete stages
of viral infection? In spite of this mineﬁeld of questions
and the intrinsic limits placed on a data set as soon as a
cohort of study is chosen, ventures into the clinical realm
are paramount and it is only this data that can ultimately
revealtheroleoftheA3familyinpotentiallycontainingHIV-
1 infection.
4.The MurineStory
In contrast to the undetermined impact human A3 proteins
have in limiting natural HIV-1 infection, systematic and
directed experiments in mice have conclusively shown that
murine A3 (mA3) is essential in containing and restricting
severalmurineretroviruses:MMTV,abetaretrovirus(mouse
mammary tumor virus), F-MuLV (Friend murine leukemia
virus), a gammaretrovirus, as well as FV (Friend virus)
[86–88]. Other murine gammaretroviruses, such as MLV
(murine leukemia virus), are resistant to mA3 restriction
[89–91]. Unlike the complex APOBEC3 locus in humans,
which contains a tandem array of seven genes, the murine
genome encodes a single APOBEC3 gene, mA3 [11, 92].
The knockout of mA3 was achieved quickly after the
identiﬁcation and cloning of A3G [93]. While a prelimi-
nary examination of the mice was relatively uninteresting,
detailed characterization of the response of these ani-
mals to speciﬁc viral challenge was both illuminating and
exciting.
Inaseriesofinformativeandelegantinvivoexperiments,
it was shown that MMTV spreads more rapidly and is
disseminated more extensively in mice lacking a functional
mA3 gene as compared to wildtype mice. The mA3 knockout
mice exhibited higher initial viral loads and a shorter
time to the development of mammary tumors [86]. It was
interesting to note that the protection aﬀorded by mA3
was not absolute; mA3 blunted, but did not completely
inhibit, MMTV infection, suggesting even partial protection
has a signiﬁcant role in in vivo pathogenesis. The molecular
mechanism of this mA3-dependent repression of infection
remains unidentiﬁed, although it does appear that this
antiviral function is exerted independently of any detectable
hypermutation or viral genome editing. In this setting
mA3-mediated containment of MMTV bears a striking
resemblance to A3A-dependent control of HIV-1 in myeloid
cells: neither inhibition requires a detectable hypermutation
function, although the block to viral infection traces to
an early post-entry step, and antiviral function is exerted
by protein expressed in target cells [22, 86]. In the case
of mA3, antiviral function was a combinatorial eﬀect of
both virion-packaged and endogenously expressed protein.
In terms of potentially harnessing the innate power of the A3
proteins, the most intriguing observation was the reporting
that pre-treatment of wildtype mice with either LPS or INF-
α upregulated mA3 expression in dendritic cells, the ﬁrst
cellsinfectedduringMMTVexposure.Thisearlyelevationof
mA3 expression directly correlated with increased resistance
to MMTV. Mice lacking mA3 were unable to restrict viral
infection despite either treatment [94]. This result speaks
directly to some of the underlying concerns regarding the
detrimental consequences of manipulating the expression
of A3G and certainly bolsters the hypothesis that increased
expression of this protein could ameliorate restriction of
HIV-1 infection.
Finally, it is interesting to note that in addition to reduc-
ing MMTV replication, virion-incorporated mA3 has also
beenshowntobe abletomarkedlyreducethe transmissionof
virus[95].MMTV,asanumberofotherretroviruses,includ-
ing HIV-1, is transmitted vertically through breastfeeding.
In an investigation examining the route of transmission,
Okeoma et al. report that not only was mA3 mRNA readily
detectable in mammary epithelial tissue but that this pack-
aged mA3 signiﬁcantly decreased MMTV transmission. In
an eﬀort to extend these observations to HIV-1 infection,
this group examined expression of the A3 genes in primary
human mammary tissue and found signiﬁcant levels of both
A3F andA3GmRNA.Whetherthisexpressiontranslatesinto
protection from the vertical transmission of HIV-1 is not yet
clear.However,thetrajectoryofthisstudyisinterestingtaken
in the context of HIV-1 infection in which breastfeeding
accounts for approximately 40% of vertical transmission
[96].
FV causes immunosuppression and leukemia in mice.
Interestingly, mice strains are diﬀerentially susceptible to
FV, and a number of genes have been implicated in the
resistance to this disease [97]. Both cell-mediated and
humoral responses appear necessary for recovery and, natu-
rally enough, the major histocompatibility complex (MHC)
locus has been identiﬁed as important. However, an essential
non-MHC gene, R e c o v e r yf r o mF r i e n dv i r u sg e n e3(Rfv3),
has also been implicated [98]. Mice strains resistant to FVMolecular Biology International 7
(e.g., C57BL/6), possess Rfv3 resistance alleles, develop high
concentrations of protective neutralizing antibodies, and
recover from viremia. Mice strains susceptible to FV infec-
tion (e.g., BALB/c) fail to mount the protective humoral
response, develop splenomegaly and erythroleukemia, and
succumb to viral infection. In a revealing study, passive
immunization of susceptible mice decreased mortality dra-
matically, suggesting that the Rfv3 locus critically inﬂuences
theproductionoftheprotectiveneutralizingantibodies[99].
The ﬁrst reporting of the genetic region encompassing
Rfv3 was in 1979 [98]. It was to be 30 years before two
groups simultaneously identiﬁed Rfv3 as mA3 [87, 88].
Using a range of both in vivo and in vitro experiments they
convincingly showed that mA3 expression was critical to the
restriction of FV infection and resulted in the suppression of
virus particle infectivity. This inhibition to viral replication
occurred after entry, but before integration, presumably
aﬀecting an early stage of FV infection (potentially reverse
transcription). The description of the restrictive capacity of
mA3 was reminiscent of the extensive data characterizing the
A3G anti-HIV-1 function. It should also be noted that, in the
FV system, mA3 function was exerted independently of any
detectable cytidine deamination activity. While the observa-
tionssupportedtheidentity ofmA3asthesuppressivefactor,
a consensus on what distinguished a resistant mA3 allele
from a susceptible allele was less discernable. Preliminary
data implicated the inﬂuence of mA3 polymorphisms on
expression level, essentially suggesting the resistant mA3
alleles were more highly expressed [87, 88, 100]. In addition,
there was also suggestion of an important role for a
coinherited B-cell-activating factor receptor (BAFF-R)a l l e l e
[101].
RecentworkprobingtheresistantversussusceptiblemA3
alleles has supported previous suggestion that an mA3 splice
variant lacking exon 5 may be more potent than a full-
length isoform [89, 102]. This latest work suggests that
the mA3Δexon 5 variant is more eﬃciently translated and
the overall combinatorial eﬀect of elevated mRNA levels
and preferential translation of the mA3Δexon 5 account for
signiﬁcantly higher levels of mA3 protein capable of potently
restricting FV infection [102]. A small number of genetic
variants within the A3 family and their respective relation-
ship to HIV-1 disease acquisition and progression have been
described: the H186R variant of A3G is associated with rapid
progression in African American populations, the C40693T
variant of A3G, as well as the homozygous loss of A3B,
maybeassociatedwithincreasedinfectionsusceptibility,and
Haplotype I of A3H may provide resistance to infection [59,
73, 74, 78]. To date, a molecular understanding of how these
variants modify (or fail to modify) HIV-1 disease is sorely
lacking. Details of the deﬁning characteristics of the resistant
mA3 alleles are of signiﬁcant interest upon contemplation
t h a ts u c hd i ﬀerences, when identiﬁed, could be thoroughly
dissected in a relevant in vivo setting, perhaps providing
valuable insight into mechanistic detail. Such details may
expand our understanding of the human versions of the A3
family and the critical polymorphisms.
What is also underscored in these reports is the im-
portance of characterizing both expression levels and allelic
diﬀerences of individual A3 genes within this family. Fluctu-
ations of A3G mRNA levels, in which A3G gene expression
is upregulated, have been reported across the immature-
to-mature diﬀerentiation transition in dendritic cells (DCs)
[65,103].TheabilityofmatureDC’storesistHIV-1infection
is well documented, and this correlative observation is
intriguing[104,105].AnobservationreportedintheMMTV
system is also suggestive: the DC’s of mice stimulated with
LPS 24 hours prior to a viral challenge exhibited a modest
(3-4-fold) increase in mA3 mRNA levels, but displayed a
signiﬁcantly increased restriction of MMTV [94]. Finally, a
recent paper examining a novel role for A3G in the sensitiza-
tion of infected cells to NK-mediated lysis suggests that small
ﬂuctuations in A3G expression levels may have profound
functional consequences [66]. These studies are interesting
for their suggestion that modest elevations of mA3 and A3G
gene expression can lead to impressive increases in viral
restriction.
5. Concluding Remarks
The unfolding story of the multifunctional characteristics
of the A3 family is fascinating. When the identiﬁcation
and characterization of A3G as a potent restriction factor
emerged, the ﬁeld raised numerous important questions and
formulated strategies for capitalizing on this natural innate
defense. Over several years, the identity of the entire A3
family of proteins as important innate restriction factors
has been established. The ability of A3G to inhibit HIV-
1Δvif infection has been analyzed by a signiﬁcant number
of laboratories, but the full complement of molecular details
on how it exerts its antiviral function has not yet been
gathered. Cytidine deamination undoubtedly occurs in the
setting of a natural viral infection, but it is not entirely
clear whether this enzymatic function is the only modality
throughwhichA3GcanobstructHIV-1invivo.Animproved
understanding of the details of how antiviral functions are
exerted is needed. In addition, the important, and likely crit-
ical contribution of additional A3 family members in vivo,
remains largely uncharacterized, although recent work using
a tissue-culture model would suggest that a collaborative
eﬀort amongst family members is essential [17]. Utilization
of both the MMTV/mA3 and FV/mA3 murine systems may
be particularly useful. They are the only in vivo models of
A3 restriction that currently exist. Alteration of the murine
genome is relatively tractable and there is a single A3 gene in
the rodent genome; potentially, mA3 genetic variants may be
assessed in this setting. Other outstanding questions include
the determination of whether any of the A3 proteins require
cofactors or post-translational modiﬁcations to function
eﬀectively. An important co-factor for APOBEC1 has been
delineated and while there is a preliminary suggestion that
A3F/3G antiviral activity requires a co-factor, no speciﬁc
proteins have been identiﬁed to date [106, 107].
Manipulation of the Vif:A3G interaction is also a viable
point of chemotherapeutic intervention. To date only one
compound speciﬁcally targeting Vif and thereby liberating
functional A3G from Vif regulation has been reported;8 Molecular Biology International
rapidly evolving technology may soon identify others [108].
A more comprehensive understanding of the interface
involved in this viral and cellular protein association could
identify new target sequences. For instance, recent identi-
ﬁcation of the transcription factor CBF-β as a member of
the ubiquitin-ligase complex recruited by Vif to degrade
A3G may prove interesting when considering novel drug
targets [109]. Liberating A3G from Vif-mediated control
has been shown to impact HIV-1 replication in vitro and
suggests elevated levels of A3G can have a signiﬁcant impact
on the kinetics of viral replication, but whether expression
levels of A3 genes can be modulated in vivo remains to be
determined. A better fundamental understanding of gene
regulationandtheimportantregulatoryelementswithinthis
family is also essential. To date only one of the promoters
within the A3 family has been identiﬁed and characterized
[85].
A more collaborative and concerted eﬀort in the exam-
ination of various cohorts is more likely to reveal whether
thereexistmeaningfulassociationsbetweenA3genesandthe
ability to completely resist or partially restrict HIV-1. In light
of the recent data being produced in the murine systems,
an examination of rapid progressors and various A3 genetic
variants is warranted. Additionally, data sets analyzing A3G
genetic variants, while relevant and useful, may have missed
important information about other family members; the
recent ﬁndings involving A3A would suggest that this gene
would also be important to examine in a number of
cohorts.
Expanded roles for members of the A3 family have
also been reported. These reports attribute an importance
to A3 proteins that extends beyond the relatively simple
arena of restriction factor. A3G’s participation in marking
cells for NK-mediated lysis would expand the reach of
the A3 family into induced innate immunity, a series of
cellular interactions important in bridging the innate and
adaptive responses. Further describing and characterizing
this observation will be important as it has potentially
important implications for treatment during acute infection
and vaccine design. In ten years the ﬁeld has exploded,
from the recognition of a single potential restriction factor
(A3G) to an impressive understanding of a family of proteins
that inﬂuence, modulate, and enhance the innate immune
response. It begs the tantalizing question: what will the next
decade bring?
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